Empagliflozin

Dr. McPhee: This is not quite the best option in this case. Empagliflozin can an excellent drug, particularly for patients with certain co-morbidities, such as heart failure, chronic kidney disease, and established or high atherosclerotic cardiovascular (ASCVD) risk. It can also help when weight loss is a goal. There is no compelling cardiorenal indication to start it ahead of another drug that is more cost-effective and could also provide benefits in preventing complications and reducing weight.

Please go back and reconsider.